Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01)
|קרן||National Institutes of Health (NIH)|
|פקולטה||Engineering, Exact Sciences, Life Sciences, Medicine|
Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments.
Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomaterials engineering, are especially encouraged.
Funding: $300,000 per year
Duration: 5 years
Research Authority due date: 10 days prior to submission
LOI (encouraged) due dates: 10.4.18, 6.11.18
Full proposal due dates: 10.5.18, 6.12.18
|עדכון אחרון||עדכון אחרון: 15/02/2018|